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Introduction: Population-wide screening for epidermal growth factor 
receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) 
gene rearrangements to inform cancer therapy in non-small-cell lung 
cancer (NSCLC) is recommended by guidelines. We estimated cost-
effectiveness of multiplexed predictive biomarker screening in meta-
static NSCLC from a societal perspective in the United States.
Methods: We constructed a microsimulation model to compare the life 
expectancy and costs of multiplexed testing and molecularly guided 
therapy versus treatment with cisplatin-pemetrexed (CisPem). All test-
ing interventions included a two-step algorithm of concurrent EGFR 
mutation and ALK overexpression testing with immunohistochemistry 
followed by ALK rearrangement confirmation with a fluorescence in 
situ hybridization assay for immunohistochemistry-positive results. 
Three strategies were included: “Test-treat” approach, where molecu-
larly guided therapy was initiated after obtainment of test results; 
“Empiric switch therapy,” with concurrent initiation of CisPem and 
testing and immediate switch to test-result conditional treatment after 
one cycle of CisPem; and “Empiric therapy” approach in which CisPem 
was continued for four cycles before start of a tyrosine kinase inhibitor.
Results: The incremental cost-effectiveness ratio for “Test-treat” 
compared with treatment with CisPem was $136,000 per quality-
adjusted life year gained. Both empiric treatment approaches had 
less favorable incremental cost-effectiveness ratios. “Test-treat” and 
“Empiric switch therapy” yielded higher expected outcomes in terms 
of quality-adjusted life years and life-years than “Empiric therapy.” 
These results were robust across plausible ranges of model inputs.
Conclusion: From a societal perspective, our cost-effectiveness 
results support the value of multiplexed genetic screening and molec-
ularly guided therapy in metastatic NSCLC.
Key Words: Multiplexed test, Non-small-cell, Lung cancer, Targeted 
therapy, Cost-effectiveness
(J Thorac Oncol. 2015;10: 586–594)
The expansion of targeted therapeutic options for metastatic non-small-cell lung cancer (NSCLC) is a welcome advance 
in a disease that historically has been resistant to treatment. 
Of the estimated 230,000 incident lung cancer cases annu-
ally, approximately 85% are diagnosed with NSCLC.1,2 Most 
patients present with advanced disease, and adenocarcinoma 
is the most common histologic subtype.2 Somatic mutations 
in epidermal growth factor receptor (EGFR) and anaplastic 
lymphoma kinase (ALK) gene rearrangements are found in 
9.5% and 3.9% of unselected NSCLCs, respectively.3 Patients 
whose tumors carry a sensitizing mutation of EGFR or ALK 
gene rearrangements experience higher response rates, longer 
progression-free survival (PFS), and improved quality of life 
when treated with a tyrosine kinase inhibitor (TKI) compared 
with platinum-based doublet chemotherapy. Guidelines rec-
ommend the ascertainment of EGFR and ALK mutational sta-
tus to help guide first-line systemic therapy in all patients with 
nonsquamous, advanced NSCLC.4 According to these recom-
mendations, over 130,000 newly diagnosed NSCLC patients 
each year should undergo predictive biomarker screening.5 
But biomarker screening appears to be underutilized in routine 
care. Only 12% of acute care hospitals in the United States 
used the EGFR assay in 2010, which represented only 5.7% 
of guideline-directed patients.4,5 In addition, recent evidence 
questions the cost-effectiveness of biomarker screening.6
Even among patients whose tumors are tested for pre-
dictive biomarkers, uncertainty surrounding the optimal 
timing of TKI therapy initiation adds to the complexity of 
treatment decision-making.7 Turn-around-time (TAT), the 
time from tissue sample acquisition to reporting of test results, 
and inadequate tissue sample for analysis may tip the scale 
toward commencing empiric treatment with chemotherapy. 
Once test results reveal the presence of an actionable muta-
tion after empiric therapy is begun, indirect evidence suggests 
that continuation of chemotherapy for four to six cycles before 
switching to a TKI may optimize outcomes.7,8 In the present 
analysis, we compared a number of TKI initiation strategies.
Multiplex detection of mutations has the advantage of tis-
sue preservation and faster TAT. To date, economic analyses of 
screening for drug sensitivity biomarkers in lung cancer have 
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restricted their focus on single biomarkers.6,9–17 We examined 
two molecular markers, EGFR mutations and ALK rearrange-
ments, for which the evidence is sufficiently mature to sup-
port population-wide screening.4 The goal of this article was 
to assess the cost-effectiveness of multiplexed predictive bio-
marker screening from a societal perspective in patients newly 
diagnosed with metastatic NSCLC living in the United States.
MATERIALS AND METHODS
Model and Treatment Strategies
We constructed a microsimulation, state-transition model 
to estimate the life expectancy and costs of four strategies: a “No 
Test” approach, treatment with cisplatin-pemetrexed (CisPem) 
chemotherapy and no biomarker testing, and two different 
empiric treatment strategies in which CisPem was initiated with 
concurrent biomarker testing. In one, the “Empiric therapy” 
strategy, chemotherapy was continued for four cycles followed 
by TKI maintenance treatment in mutation-positive patients. In 
the other, the “Empiric switch therapy,” patients initiated first-
line chemotherapy, and those with mutation-positive tumors 
switched to a TKI immediately upon return of test results; and 
finally, the “Test-treat” strategy, in which molecularly guided 
treatment was initiated only after results of testing became avail-
able. The simulated study population composed of newly diag-
nosed stage IV NSCLC patients with nonsquamous histology.
Figure 1 depicts the structure of the model. For all test-
ing strategies, patients entered the model in the prescreen state 
on the day the test was ordered. If the sample was suitable 
for testing, the patient transitioned to the test sequence health 
states. With a daily cycle length, we were able to model wait 
times for test results before initiation of therapy. Patients with 
insufficient tumor samples from initial diagnostic samples 
transitioned to the rebiopsy prescreen state to account for 
elapsed time in determining appropriateness for a rebiopsy and 
for performing the procedure. Patients who did not undergo a 
rebiopsy, or whose rebiopsy samples were inadequate for test-
ing, transitioned to the treatment states. Multiplexed molecu-
lar testing proceeded according to a two-step test sequence: 
concurrent EGFR mutation and ALK overexpression assays 
followed by ALK fluorescence in situ hybridization (FISH) 
confirmation for ALK immunohistochemistry (IHC)-positive 
results (1+, 2+, or 3+).4 Mortality risk in the above health 
states was modeled based on the natural history of advanced 
NSCLC for the “Test-treat” approach and the first-line CisPem 
therapy for the empiric treatment strategies.
Patients in the “No test” strategy entered the model in 
the first-line CisPem treatment state (Fig. 1). Upon progres-
sion on each therapy, patients transitioned to the next line of 
therapy based on treatment conditional disease risk of progres-
sion. Treatment sequences for the other strategies (Table 1) 
followed the same model structure.
For the main analysis, we chose a time horizon of 2 
years to capture the major health and economic consequences 
in metastatic NSCLC. This duration obviated the need for 
projecting survival outcomes beyond the primary clinical trial 
data.18 Benefits and costs were discounted at 3% per annum. 
Analyses were performed in TreeAge Pro 2013 (TreeAge 
Software, Inc., Williamstown, MA).
Natural History
We used data from Surveillance, Epidemiology, and End 
Results-Medicare to model the natural history of untreated, 
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FIGURE 1.  Model structure depicting health states and transitions.
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metastatic NSCLC for simulated patients who were await-
ing molecular test results. Predicted probabilities from a 
Cox proportional hazards model for incident Surveillance, 
Epidemiology, and End Results’ (SEER) cases with Stage 
IV NSCLC and a pathologic diagnosis of nonsquamous his-
tology, aged 66–69 years with diagnoses between 2007 and 
2009, who were managed with best supportive care were gen-
erated. The model was weighted using the inverse conditional 
probability of exposure to chemotherapy to balance observ-
able covariates between treatment naive and chemotherapy-
treated patients. Time dependent transitional probabilities for 
the simulation model were calibrated to the predicted survival 
probabilities from the Cox proportional hazard model using a 
piecewise-exponential approach.
Clinical Outcomes
Randomized clinical trials (RCTs) for initiation and main-
tenance therapy with erlotinib and crizotinib in EGFR mutation 
and ALK rearrangement-positive patients, respectively, were 
identified for calculating treatment-conditional progression and 
survival estimates. Efficacy data for other therapies were pulled 
from RCTs that enrolled molecularly unselected patients. The 
trial-based median estimates for treatment-specific overall sur-
vival and PFS were used as calibration targets. Transition prob-
abilities were calculated using a constant hazard assumption.
Quality of Life
We estimated utilities based on a mixed model, which 
included parameters for best tumor response and toxici-
ties usually encountered with chemotherapy treatments in 
NSCLC (neutropenia, febrile neutropenia, fatigue, diarrhea, 
nausea and vomiting, rash, and hair loss).19 We used rates for 
best tumor response and grades 3 and 4 adverse drug events 
(ADEs) from RCTs to calculate treatment-specific utilities 
based on the mixed model (Table 2).19 Disutilities for ADEs 
were incorporated in the first month of therapy.11,20
Genomic Markers
Prevalence rates of biomarkers were drawn from a popu-
lation-based registry (Table 2) of 10,000 NSCLC patients who 
were enrolled for routine screening of predictive biomarkers.3 
The cumulative TAT for test results is congruent with guide-
lines, which recommend that EGFR and ALK testings both be 
completed within 10 working days of receiving the specimen 
in the laboratory.4
We estimated that 30% of patients would undergo a 
rebiopsy, and 85% of repeat biopsies would yield adequate 
samples for molecular testing.10 The distribution of repeat 
biopsy techniques (bronchoscopic, or transthoracic needle 
aspiration of primary cancer, and metastatic site needle aspi-
rations) and pneumothorax complication rates were based on 
a prior analysis.10
We used ALK FISH positivity as the reference standard 
for presence of ALK rearrangements.4,25 Estimates for IHC test 
performance were taken from the largest published case series 
evaluating a novel 5A4 monoclonal antibody (Table 1).28
Costs
Cancer-related medical costs, costs of travel, and patient 
time spent seeking medical care were included in the model 
(Table 2). We used the Centers for Medicare and Medicaid 
Services reimbursement rates for each biomarker assay in our 
base-case analysis and for other direct medical costs, includ-
ing drug administration, imaging, and ADEs. Costs for treat-
ment specific ADEs were assumed to accrue in the first month 
of therapy.11,20 The average sale price and average wholesale 
price were used to value injectable and orally administered 
drugs, respectively. With the exception of CisPem chemother-
apy, which was administered up to four cycles, patients were 
assumed to accrue drug-related costs up to the time of pro-
gression. Costs for rebiopsy and related complications were 
derived from the analysis by Handorf et al.10 The cost for treat-
ing progressive disease was based on lung cancer attributable 
TABLE 1  Strategies
Strategy Test Treatment
No test None CisPema ► Pem ► DTX ► Erlot ►BSC
Empiric therapyb EGFR/ALK IHC ► ALK FISH for ALK IHC 1–3+ Empiric CisPem × 4 cycles ► test result conditional treatment:
EGFR +: Erlot ► DTX ► BSC
ALK +: Criz ► DTX ► BSC
Other: CisPema ► Pem ► DTX ► Erlot ►BSC
Empiric- switch therapyc EGFR/ALK IHC ► ALK FISH for ALK IHC 1–3+ Empiric CisPem × 1 cycle ► test result ► test result conditional treatment:
EGFR +: Erlot ► CisPema ► DTX ► BSC
ALK +: Criz ► CisPema ► DTX ► BSC
Other: CisPema ► Pem ► DTX ► Erlot ►BSC
Test-treat EGFR/ALK IHC ► ALK FISH for ALK IHC 1–3+  EGFR +: Erlot ► CisPema ► DTX ►BSC
ALK +: Criz ► CisPema ► DTX ►BSC
Other: CisPema ► Pem ► DTX ►Erlot ► BSC
aCisPem therapy was administered for up to four cycles; upon progression on CisPem, patients transitioned to the next line of therapy.
bTKI maintenance treatment was initiated in presence of drug-sensitizing mutations upon completion of four cycles of CisPem.
cPatients with drug-sensitizing mutations switched to a TKI at time of test results after receiving one cycle of empiric CisPem therapy.
CisPem, cisplatin and pemetrexed doublet; Pem, pemetrexed; DTX, docetaxel; Erlot, erlotinib; BSC, best-supportive care; Criz, crizotinib; ALK, anaplastic lymphoma kinase; IHC, 
immunohistochemistry; FISH, fluorescence in situ hybridization.
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TABLE 2.  Model Parameters and Ranges for Sensitivity Analyses
Variable Base Case Low High Source
Overall survival (months)
  Cisplatin plus pemetrexed 11.8 10.4 13.2 (21)
  Pemetrexed 13.9 12.8 16.0 (22)
  Docetaxel 8.0 6.4 9.6 (13)
  Erlotinib (1st line) 19.3 14.7 26.8 (23)
  Erlotinib (maintenance)a 24.0 19.2 28.8 (24)
  Crizotinib 20.3 18.1 26.8 (25)
  Erlotinib (third line) 6.7 5.5 7.8 (26)
  Best supportive care 4.5 4.3 4.9 SEER-Medicare
Progression-free survival (months)
  Cisplatin plus pemetrexed 5.3 4.8 5.7 (21)
  Pemetrexed 4.1 3.2 4.6 (22)
  Docetaxel 3.3 2.6 4.0 (13)
  Erlotinib (first line) 9.7 8.4 12.3 (23)
  Erlotinib (maintenance) 10.3 8.2 12.4 (24)
  Crizotinib 7.7 6.0 8.8 (25)
  Erlotinib (third line) 2.2 1.9 2.8 (26)
Health state utilities
  With best response and adverse events
   Cisplatin plus pemetrexed 0.59 0.51 0.66 (19,21)
   Pemetrexed 0.60 0.54 0.65 (19,22)
   Docetaxel 0.48 0.37 0.59 (13,19)
   Erlotinib (first line) 0.64 0.58 0.70 (19,23)
   Erlotinib (maintenance) 0.66 0.61 0.71 (19,24)
   Crizotinib 0.64 0.58 0.70 (19,25)
   Erlotinib (third line) 0.56 0.49 0.64 (19,26)
   No treatment 0.46 0.36 0.55 (19)
  With best response and no adverse events
   Cisplatin plus pemetrexed 0.62 0.56 0.67 (19,21)
   Pemetrexed 0.60 0.55 0.66 (19,22)
   Docetaxel 0.57 0.51 0.64 (13,19)
   Erlotinib (first line) 0.65 0.60 0.71 (19,23)
   Erlotinib (maintenance) 0.66 0.61 0.71 (19,24)
   Crizotinib 0.66 0.60 0.71 (19,25)
   Erlotinib (third line) 0.59 0.53 0.65 (19,26)
Probabilities (%)
  EGFR mutation positive 9.5 8.9 10.7 (3)
  ALK rearrangement positive 3.9 3.5 4.3 (3)
  Inadequate tissue—initial biopsy 37.7 26 49 (27)
  Re-biopsy 30 15 45 Expert opinion
  Inadequate tissue—rebiopsy 15 10 25 (10)
  ALK IHC specificity 96 95 100 (28)
  ALK IHC sensitivity 100 100 100 (28)
  Proportion of patients tested 100 5.7 100 (5)
TAT (days)b
  With no re-biopsy 12 7 16 (4), expert opinion
  With re-biopsy 24 13 34 (4), expert opinion
Costs, 2013 US$
  EGFR mutation assay $201 $201 $718 (29,30)
  ALK IHC assay $136 $136 $217 (29,30)
  ALK FISH assay $489 $489 $598 (29,30)
(Continued)
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costs in the last year of life.34 All costs in the model were 
adjusted to 2013 values using the gross domestic product 
deflator series.37
Cost-Effectiveness Analysis
We calculated the incremental cost-effectiveness 
by ranking the strategies in order of increasing effective-
ness. Strongly dominated strategies, those that had a lower 
or equal effectiveness and higher costs, were eliminated. 
Incremental cost-effectiveness ratios (ICERs) were cal-
culated for each strategy in relation to the next best strat-
egy. The ICER is a ratio of the difference in mean costs 
divided by the difference in mean quality-adjusted life years 
(QALYs). Strategies with a higher ICER that were less 
effective than another strategy were eliminated by extended 
dominance. The ICERs were recalculated for the remaining 
nondominated strategies.38
Sensitivity Analyses
We conducted sensitivity analyses to evaluate which 
parameters were most influential on model results. Where 
available, the ranges used for the parameters corresponded 
to the 95% confidence intervals (Table 2). Costs were varied 
±20%, and plausible ranges for TATs were used based on 
expert opinion. We also simulated the lifetime (5 year) costs 
and effectiveness where prognosis beyond trial observation 
period was modeled using exponential distributions. In addi-
tion, model outputs were generated based on commercial 
prices for molecular assays and proportion of patients tested. 
We also ran a sensitivity analysis for the transition probabil-
ity of dying while awaiting test results based on treatment 
naive patients who were randomized to best supportive care 
in a RCT.39 Finally, we conducted a threshold sensitivity 
analysis by varying the TAT for testing and results to deter-
mine the break-even point at which the expected benefits of 
Cisplatin and pemetrexed
  Drug acquisition (per 21 day cycle) $5721 $4577 $6865 (31)
  Premedication $254 $203 $305 (31,32)
  Administration, monitoring $446 $357 $535 (29,30)
  Adverse drug event treatment $760 $608 $912 (29–33)
Pemetrexed maintenance
  Drug acquisition (per 21 day cycle) $5689 $4551 $6827 (31)
  Premedication $6 $5 $7 (31,32)
  Administration, monitoring $276 $221 $331 (29,30)
  Adverse drug event treatment $304 $243 $365 (29–33)
Docetaxel
  Drug acquisition (per 21 day cycle) $937 $750 $1124 (31)
  Premedication $8 $6 $10 (31,32)
  Administration, monitoring $329 $263 $395 (29,30)
  Adverse drug event treatment $2525 $2020 $3030 (29–33)
Erlotinib
  Drug acquisition (per 21 day cycle) $3982 $3186 $4778 (32)
  Premedication $0 $0 $0 (31,32)
  Administration, monitoring $165 $132 $198 (29,30)
  Adverse drug event treatment
   First line $358 $286 $430 (29–33)
   Third line $727 $582 $872 (29–33)
   Maintenance $358 $286 $430 (29–33)
Crizotinib
  Drug acquisition (per 21 day cycle) $8041 $6433 $9649 (32)
  Premedication $0 $0 $0 (31,32)
  Administration, monitoring $165 $132 $198 (29,30)
  Adverse drug event treatment $550 $440 $660 (29–33)
 Disease progression, per month $5457 $5,283 $5605 (34)
 Patient time, per hour $19 $10 $29 (35)
 Travel, per 30 mile round trip $15 $8 $23 (36)
aProbability of survival = 0.6; median survival probability not reported.
bIncludes time for delivery of tissue sample to the laboratory.
ALK, anaplastic lymphoma kinase; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; EGFR, epidermal growth factor receptor; TAT, turnaround time from 
receipt of specimen to report of test results; SEER, Surveillance, Epidemiology, and End Results.
TABLE 2. (Continued )
Variable Base Case Low High Source
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the “Empiric therapy” approach would be equivalent to the 
“Test-treat” strategy.
RESULTS
Multiplexed testing approaches of “Test-treat” and 
“Empiric switch” were most effective (Table 3). Both yielded 
an average life expectancy of 0.97 life years (LYs) and 0.56 
QALYs, which represents 0.04 and 0.03 increases in LYs and 
QALYs, respectively, compared with no test and treatment 
with standard chemotherapy. The “Empiric therapy” approach, 
in which chemotherapy was continued for four cycles before 
initiation of molecularly guided therapy, was less effective 
(0.95 LYs and 0.55 QALYs). Because the “Empiric switch” 
approach was more expensive than the “Test-treat” strategy 
(but equally effective), it was ruled out by strong dominance. 
The “Empiric therapy” approach was eliminated by extended 
dominance because it was associated with a higher ICER than 
the “Test-treat” approach. Compared with the “No test” strat-
egy, the “Test-treat” approach of concurrent EGFR mutation 
and ALK IHC testing followed by ALK FISH confirmation 
before initiation of any therapy yielded an ICER of $136,000 
per additional QALY (0.03 additional QALYs and $4082 extra 
spending). Without adjustment for quality of life, the “Test-
treat” approach had an ICER of $102,000 per LY gained com-
pared with the “No test” strategy.
Sensitivity Analyses
Changing the parameters values over ranges listed in 
Table 2 did not impact the rank order of the strategies. Also, 
both empiric treatment strategies remained dominated. A 
comparison of the nondominated strategies revealed that the 
most influential parameters were utilities and acquisition costs 
for TKIs (Fig. 2). We found that the ICER for the “Test-treat” 
approach compared with the “No test” strategy ranged from 
$124,000 to $157,000 per additional QALY, with high and 
low utility values, respectively; and from $83,000 to $190,000 
per QALY gained when costs of TKI therapy were varied by 
minus and plus 20%, respectively. In all other scenarios, the 
ICER for “Test-treat” compared with “No test” ranged from 
$130,000 to $150,000 per QALY.
Commercial prices for assays had a small effect on the 
ICER ($148,000 per QALY for the “Test-treat” vs. “No test” 
strategy). Extrapolation of long-term survival increased the 
ICER for “Test-treat” to $148,000 per QALY compared with 
“No Test.” With a trial-based mortality risk in the pretreatment 
health states (using a piecewise exponential model with sur-
vival probabilities of 97% and 90% at 1 and 2 months after 
diagnosis, respectively), the same dominance pattern was 
observed and the ICER remained stable for the “Test-treat” 
strategy compared with “No Test” ($153,000/QALY).39
Varying the proportion of patients for whom multi-
plexed molecular testing is ordered showed that decreasing 
this proportion to 5.7%, from 100% in the base-case analy-
sis, would lower the outcomes in terms of expected QALYs to 
0.54 for all testing strategies.5 Finally, our threshold analysis 
of TATs revealed that increasing the wait times for testing and 
results by 1.5-fold of the base-case estimates would render the 
“Empiric therapy” approach equivalent in terms of expected 
benefits to the “Test-treat” strategy, at 0.55 QALYs each.
DISCUSSION
Concurrent EGFR mutation and ALK IHC testing with 
ALK FISH confirmation for tumors that overexpress the 
ALK protein before initiation of therapy yielded an ICER 
of $136,000 per QALY gained compared with no testing 
and treatment with chemotherapy alone. Whether or not an 
ICER of $136,000 provides good value is contingent upon the 
willingness-to-pay threshold, which serves as a guide of how 
much society is willing to pay for an additional QALY. The 
World Health Organization (WHO) defines interventions with 
ICERs within three times the gross domestic product per capita 
as being cost-effective (approximately $155,000 in the United 
States in 2014).40 Others posit that a threshold of $200,000 
per QALY may be more appropriate based on empirical data 
of ICERs for often used interventions.41,42 Using these bench-
marks, our results suggest that multiplexed testing followed 
by molecularly guided therapy in metastatic NSCLC provides 
good value from a societal perspective.
Our simulation study confirms that waiting for test 
results before initiation of treatment optimizes outcomes in 
newly diagnosed patients with metastatic NSCLC.7 Although 
empiric therapy in which chemotherapy is initiated concur-
rently with testing for mutations, followed by an immediate 
switch to molecularly guided therapy at the time test results 
become available yielded the same life expectancy as the 
test then treat approach, the former strategy was dominated 
TABLE 3.  Cost-Effectiveness Resultsa
Strategy LYs
Incremental 
LYsb QALYs
Incremental 
QALYsb Costc
Incremental 
Costb ICER ($/LY) ICER ($/QALY)
Standard care: No test, CisPem 0.93 — 0.53 — $79,331 — — —
Empiric therapy 0.95 0.02 0.55 0.02 $82,762 $3431 Extended 
dominance
Extended 
dominance
Test-treat 0.97 0.02 0.56 0.01 $83,413 $651 102,000 136,000
Empiric switch therapy 0.97 0.00 0.56 0.00 $86,645 $3232 Dominated Dominated
aCosts and life expectancy outcomes were discounted at a 3% annual rate. The “Empiric therapy” approach composed of CisPem continuation for four cycles before start of 
molecularly guided therapy. In the “Test-treat” approach, molecularly guided therapy was initiated after ascertainment of test results. In the “Empiric switch therapy,” concurrent 
initiation of CisPem and testing was modeled followed by an immediate switch to test-result conditional treatment after one cycle of CisPem.
bCompared with the next-best strategy in terms of effectiveness.
c2013 $US.
LYs, life-years; QALYs, quality-adjusted life-years; ICER, incremental cost-effectiveness ratio; CisPem, cisplatin and pemetrexed doublet.
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because it was more expensive. Continuation of empiric 
chemotherapy for four cycles before switching to test-result 
conditional treatment yielded less favorable outcomes than 
the above two approaches, both in terms of QALYs and LYs. 
This strategy was eliminated by extended dominance. These 
results were robust to variations over plausible ranges of 
model parameters.
In sensitivity analyses, the ICER was highly sensitive 
to drug acquisition costs. At lower TKI prices (80% of brand 
name product price), the ICER for the “Test-treat” strategy 
decreased to $83,000 per QALY compared with standard treat-
ment with chemotherapy. Over time, once generic versions of 
TKIs become available, these innovations will confer even 
better value. The optimal price point that maximizes social 
welfare, while minimizing the impact on technological inno-
vation, is outside the scope of this analysis. However, growing 
concerns over the increasing cost burden of these innovations 
on patients deserve scrutiny.43–45 Patient access to these drugs 
may be impeded by onerous out of pocket costs. One way to 
attenuate the impact of cost sharing may be through value-
based benefit design. Arguably, breakthrough therapies that 
offer substantial improvement in outcomes and are placed into 
lower cost sharing tiers would benefit society as a whole from 
healthier patients who remain productive, as they are able to 
access these beneficial treatments.
We were unable to identify published economic analy-
ses that examined multiplexed testing in advanced NSCLC. 
Handorf et al. evaluated the cost-effectiveness of molecularly 
guided first-line therapy using EGFR mutation testing in the 
United States from a payer perspective. The ICERs for test-
ing with and without rebiopsy and EGFR mutation guided 
treatment ranged from $110,644 to $122,219 per QALY 
gained compared with treatment with a  carboplatin-paclitaxel 
doublet.10 Similar to our analysis, the cost-effectiveness results 
from that study support the value of molecularly guided 
therapy. Another recently published study examined the cost-
effectiveness of ALK rearrangement testing alone before 
first-line crizotinib treatment in ALK-positive tumors or 
cisplatin-gemcitabine combination chemotherapy in wild-
type tumors.6 From a Canadian public health perspective, that 
analysis generated an ICER of $255,970 per additional QALY 
for molecularly guided therapy compared with chemotherapy. 
The authors concluded that genetic testing and treatment with 
molecularly guided therapy was not cost-effective. Unlike the 
Canadian study, we combined multiplexed testing in our anal-
ysis of the two molecular markers that are guideline-recom-
mended for population-wide screening in advanced NSCLC, 
which de facto produced better outcomes for the molecular 
testing strategy because more patients benefit from testing.
Our results are subject to modeling assumptions and 
need to be interpreted in this context. For example, due to 
treatment crossover after progression and lack of direct com-
parisons in RCTs, we relied on single-arm data for our param-
eters. Furthermore, we used data from PROFILE 1007, a 
phase 3 RCT of second-line crizotinib, to inform hazard rates 
in our model for overall survival and PFS.25 These estimates 
apply to a small subset of patients in our model, those with 
ALK rearrangement-positive status. Any bias introduced into 
the model would thus be marginal given the size of this sub-
group.46 Overall, varying the hazard rates for treatment effects 
in sensitivity analyses revealed that the base-case results were 
robust to these assumptions. Also, we used Medicare reim-
bursements as a proxy for the societal costs of test assays. 
However, the true costs of the tests may vary across provid-
ers. But even with commercial test prices, the ICER for the 
“Test-treat” compared with the “No test” strategy increased 
to $148,000 per additional QALY, which is still below com-
monly acceptable willingness-to-pay thresholds.41
In summary, our analysis suggests that multiplexed test-
ing for EGFR mutations and ALK overexpression with an 
IHC assay followed by ALK rearrangement confirmation with 
FISH for IHC-positive results and biomarker conditional treat-
ment is a cost-effective strategy compared with treatment with 
chemotherapy and no testing in metastatic NSCLC. Empiric 
ICER ($/QALY) 
80,000 100,000   120,000   140,000   160,000 180,000   200,000
Test-treat vs. Test
TKI price
Utilities
Probability of progression and mortality with
therapy
EGFR mutation frequency
Probability of rebiopsy
Discount rate
Probability of adequate initial tissue sample
ALK rearrangement frequency
TAT
Cost of BSC
ALK IHC test specificity
FIGURE 2.  Sensitivity analyses. 
Tornado diagram of influential 
parameters on the incremental 
cost-effectiveness ratio (ICER) of 
“Test-treat” versus “No Test” strate-
gies. TKI, tyrosine kinase inhibitor; 
EGFR, epidermal growth factor drug 
sensitizing mutation; ALK, anaplastic 
lymphoma kinase rearrangement; 
TAT, turn-around time; BSC, best-
supportive care; IHC, immunohis-
tochemistry; QALY, quality-adjusted 
life year.
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CisPem therapy for four cycles with concurrent molecular 
testing before initiation of TKI maintenance therapy gener-
ated inferior outcomes compared with waiting for test results 
before treatment and compared with “Empiric switch therapy” 
in which chemotherapy initiated treatment was immediately 
switched to molecularly guided therapy when test results 
became available.
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